Levocetirizine: an update

Research output: Contribution to journalLiterature review

30 Citations (Scopus)


Histamine plays a prominent and diverse role in the pathophysiology of allergic disease and therapeutic intervention is therefore typically focused on blocking the effects of this biogenic amine. A new antihistamine, levocetirizine, is the R-enantiomer of cetirizine dihydrochloride and like its parent compound undergoes minimal hepatic metabolism. Levocetirizine has pharmacodynamically and pharmacokinetically favourable characteristics, including high bioavailability, rapid onset of action, limited distribution and a low degree of metabolism. Clinical trials indicate that it is safe and effective for the treatment of allergic rhinitis and chronic urticaria with a minimal number of untoward effects. Furthermore, several recent studies have demonstrated that, in addition to its being a potent antihistamine, levocetirizine has several anti-inflammatory effects that are observed at clinically relevant concentrations that may enhance its therapeutic benefit.

Original languageEnglish
Pages (from-to)2711-2715
Number of pages5
JournalCurrent Medicinal Chemistry
Issue number22
Publication statusPublished - 2006


  • levocetirizine
  • antihistamine
  • allergy
  • anti-inflammatory
  • chronic idiopathic urticaria
  • persistent allergic rhinitis
  • healthy adult volunteers
  • placebo-controlled trial
  • quality-of-life
  • double-blind
  • histamine
  • asthma
  • desloratadine
  • cetirizine


Dive into the research topics of 'Levocetirizine: an update'. Together they form a unique fingerprint.

Cite this